913 related articles for article (PubMed ID: 31388093)
41. Intestinal Dysbiosis and Development of Cardiometabolic Disorders in Childhood Cancer Survivors: A Critical Review.
Morel S; Delvin E; Marcil V; Levy E
Antioxid Redox Signal; 2021 Jan; 34(3):223-251. PubMed ID: 32390455
[No Abstract] [Full Text] [Related]
42. Gut Microbiota Mediates the Protective Effects of Dietary Capsaicin against Chronic Low-Grade Inflammation and Associated Obesity Induced by High-Fat Diet.
Kang C; Wang B; Kaliannan K; Wang X; Lang H; Hui S; Huang L; Zhang Y; Zhou M; Chen M; Mi M
mBio; 2017 May; 8(3):. PubMed ID: 28536285
[TBL] [Abstract][Full Text] [Related]
43. Intestinal microbiota and nonalcoholic steatohepatitis.
Brandl K; Schnabl B
Curr Opin Gastroenterol; 2017 May; 33(3):128-133. PubMed ID: 28257306
[TBL] [Abstract][Full Text] [Related]
44. Western diets, gut dysbiosis, and metabolic diseases: Are they linked?
Martinez KB; Leone V; Chang EB
Gut Microbes; 2017 Mar; 8(2):130-142. PubMed ID: 28059614
[TBL] [Abstract][Full Text] [Related]
45. Reduced obesity, diabetes, and steatosis upon cinnamon and grape pomace are associated with changes in gut microbiota and markers of gut barrier.
Van Hul M; Geurts L; Plovier H; Druart C; Everard A; Ståhlman M; Rhimi M; Chira K; Teissedre PL; Delzenne NM; Maguin E; Guilbot A; Brochot A; Gérard P; Bäckhed F; Cani PD
Am J Physiol Endocrinol Metab; 2018 Apr; 314(4):E334-E352. PubMed ID: 28874357
[TBL] [Abstract][Full Text] [Related]
46. Gut barrier disruption and chronic disease.
Martel J; Chang SH; Ko YF; Hwang TL; Young JD; Ojcius DM
Trends Endocrinol Metab; 2022 Apr; 33(4):247-265. PubMed ID: 35151560
[TBL] [Abstract][Full Text] [Related]
47. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
48. Cationic Polystyrene Resolves Nonalcoholic Steatohepatitis, Obesity, and Metabolic Disorders by Promoting Eubiosis of Gut Microbiota and Decreasing Endotoxemia.
Zhu A; Chen J; Wu P; Luo M; Zeng Y; Liu Y; Zheng H; Zhang L; Chen Z; Sun Q; Li W; Duan Y; Su D; Xiao Z; Duan Z; Zheng S; Bai L; Zhang X; Ju Z; Li Y; Hu R; Pandol SJ; Han YP
Diabetes; 2017 Aug; 66(8):2137-2143. PubMed ID: 28446519
[TBL] [Abstract][Full Text] [Related]
49. Akkermansia muciniphila: key player in metabolic and gastrointestinal disorders.
Macchione IG; Lopetuso LR; Ianiro G; Napoli M; Gibiino G; Rizzatti G; Petito V; Gasbarrini A; Scaldaferri F
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):8075-8083. PubMed ID: 31599433
[TBL] [Abstract][Full Text] [Related]
50. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
Kirpich IA; Marsano LS; McClain CJ
Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
[TBL] [Abstract][Full Text] [Related]
51. Potential mechanisms linking gut microbiota and portal hypertension.
Baffy G
Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
[TBL] [Abstract][Full Text] [Related]
52. Role of vitamin D on gut microbiota in cystic fibrosis.
Kanhere M; Chassaing B; Gewirtz AT; Tangpricha V
J Steroid Biochem Mol Biol; 2018 Jan; 175():82-87. PubMed ID: 27818276
[TBL] [Abstract][Full Text] [Related]
53. Oral Administration of Porphyromonas gingivalis Alters the Gut Microbiome and Serum Metabolome.
Kato T; Yamazaki K; Nakajima M; Date Y; Kikuchi J; Hase K; Ohno H; Yamazaki K
mSphere; 2018 Oct; 3(5):. PubMed ID: 30333180
[TBL] [Abstract][Full Text] [Related]
54. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?
Brandl K; Schnabl B
Expert Rev Gastroenterol Hepatol; 2015; 9(8):1069-76. PubMed ID: 26088524
[TBL] [Abstract][Full Text] [Related]
55. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.
Vallianou N; Stratigou T; Christodoulatos GS; Dalamaga M
Curr Obes Rep; 2019 Sep; 8(3):317-332. PubMed ID: 31175629
[TBL] [Abstract][Full Text] [Related]
56. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.
Zhou D; Pan Q; Xin FZ; Zhang RN; He CX; Chen GY; Liu C; Chen YW; Fan JG
World J Gastroenterol; 2017 Jan; 23(1):60-75. PubMed ID: 28104981
[TBL] [Abstract][Full Text] [Related]
57. Gut Microbiota and Metabolic Disorders: Advances in Therapeutic Interventions.
Akash MSH; Fiayyaz F; Rehman K; Sabir S; Rasool MH
Crit Rev Immunol; 2019; 39(4):223-237. PubMed ID: 32421966
[TBL] [Abstract][Full Text] [Related]
58. Beneficial Effects of Non-Encapsulated or Encapsulated Probiotic Supplementation on Microbiota Composition, Intestinal Barrier Functions, Inflammatory Profiles, and Glucose Tolerance in High Fat Fed Rats.
Lee S; Kirkland R; Grunewald ZI; Sun Q; Wicker L; de La Serre CB
Nutrients; 2019 Aug; 11(9):. PubMed ID: 31443365
[TBL] [Abstract][Full Text] [Related]
59. Diet-Independent Correlations between Bacteria and Dysfunction of Gut, Adipose Tissue, and Liver: A Comprehensive Microbiota Analysis in Feces and Mucosa of the Ileum and Colon in Obese Mice with NAFLD.
Gart E; Souto Lima E; Schuren F; de Ruiter CGF; Attema J; Verschuren L; Keijer J; Salic K; Morrison MC; Kleemann R
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577415
[TBL] [Abstract][Full Text] [Related]
60. Understanding the Holobiont: How Microbial Metabolites Affect Human Health and Shape the Immune System.
Postler TS; Ghosh S
Cell Metab; 2017 Jul; 26(1):110-130. PubMed ID: 28625867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
